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The brain is a lipid-rich organ containing mostly complex polar phospholipids, sphingolipids, gangliosides and
cholesterol. These lipids are involved in the structure and function of cell membranes in the brain. The glyc-
erophospholipids in the brain contain a high proportion of polyunsaturated fatty acids (PUFA) derived from the
essential fatty acids, linoleic acid and alpha-linolenic acid. The main PUFA in the brain are docosahexaenoic
acid (DHA, all cis 4,7,10,13,16,19-22:6) derived from the omega 3 fatty acid, alpha-linolenic acid, and arachi-
donic acid (AA, all cis 5,8,11,14-20:4) and docosatetraenoic acid (all cis 7,10,13,16-22:4), both derived from the
omega 6 fatty acid, linoleic acid. Experimental studies in animals have shown that diets lacking omega 3 PUFA
lead to substantial disturbances in neural function, which in most circumstances can be restored by the inclusion
of omega 3 PUFA in the diet. In the past 10 years there has been an emerging interest in treating neuropsy-
chological disorders (depression and schizophrenia) with omega 3 PUFA. This paper discusses the clinical stud-
ies conducted in the area of depression and omega 3 PUFA and the possible mechanisms of action of these
PUFA. It is clear from the literature that DHA is involved in a variety of processes in neural cells and that its
role is far more complex than simply influencing cell membrane properties.
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Introduction
Omega 3 fatty acids in the brain
The brain contains the second highest concentration of
lipids in the body, after adipose tissue, with 36-60% of
nervous tissue being lipids. The lipids in brain are complex
lipids and include glycerophospholipids, sphingolipids
(sphingomyelin and cerebrosides), gangliosides and choles-
terol, with little or no triglycerides and cholesterol esters.
Brain glycerophospholipids contain a high proportion of
PUFA, derived from the two main essential fatty acids,
mainly docosahexaenoic acid (DHA, 22:6 omega 3), ara-
chidonic acid (AA, 20:4 omega 6) and docosatetraenoic
acid (22:4 omega 6). The proportion of DHA in the glyc-
erophospholipids of brain grey matter is higher than the
white matter' and phosphatidylethanolamine and phos-
phatidylserine contain the most DHA amongst all the
glycerophospholipids. The DHA content of the adult cere-
bral cortex is approximately 3% of the dry weight and
0.4% of the white matter.' The omega 6 fatty acid content
(20:4 omega 6 plus 22:4 omega 6) ofthe cerebral cortex is
similar to that ofthe DHA content. In white matter there is
a higher proportion of omega 6 than omega 3 PUFA.'
What is the role of DHA in the brain?
The classical way of studying the role of DHA in the brain
has been to examine what happens in animals fed diets
lacking omega 3 PUFA. These studies reveal that such
diets lead to significant reductions in the level of DHA in
brain lipids. When there is a reduced level of DHA in the
brain, many dramatic changes in brain function have been
reported including changes in size of neurons, changes in
learning & memory, changes in the auditory and olfactory
responses to stimuli, and changes in nerve growth factor
levels. A recent report described an increase in depression
and aggression scores in rats deprived of dietary omega 3
fatty acids for 15 weeks after weaning.^
Various mechanisms have been suggested to account for
these physiological changes in the brain. Mostly, the
changes appear to be related to changes in membrane
function, however recent studies have shown that DHA can
also influence gene expression in the brain. In summary,
in the brain DHA plays a crucial role in:
Membrane related events
[a] membrane order (membrane fluidity) which can influ-
ence the function of membrane receptors such as rhodopsin
through effects on the membrane environment and on bind-
ing to the membrane protein,'''' [b] regulation of dopa-
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minergic and serotonergic neurotransmission,' [c] regula-
tion of membrane-bound enzymes (Na/K-dependent
ATP'ase),* [d] signal transduction via effects on inositol
phosphates, DAG and protein kinase C,' and [e] regula-
tion of glucose uptake,* perhaps via effects on brain glu-
cose transporters.'
Metabolic events
[a] regulation of the synthesis of eicosanoids derived
from AA,'" [b] DHA can serve as a precursor of docosa-
trienes" and 17S resolvins, novel anti-inflammatory me-
diators.'^ The docosatrienes (17S-hydroxy-containing
docosanoids) and 17S series resolvins are biosynthesised
via enzymatic oxygenation and are potent regulators of
both leukocytes (reducing infiltration in vivo) and glial
cells (blocking their cytokine production).'^ It is not
known whether these bioactive mediators derived from
DHA are responsible for some of the beneficial actions
reported following dietary supplementation with DHA.
Bazan" has also described a 10,17S-docosatriene called
neuroprotectin Dl (NPDl) which he proposes protects
the brain and retina from oxidative stress-induced apop-
tosis. NPDl is formed through enzyme-mediated steps
involving phospholipase A2 followed by a 15-
lipoxygenase-like activity."
DHA can also undergo non-enzymatic free-radical
catalysed oxidation in the brain to form F2-isoprostane-
like compounds that are known as F4-neuroprostanes and
highly reactive A/J-ring neuroprostanes which may pro-
vide a marker of oxidative injury in the brain. These re-
sults suggest that oxidative stress is ongoing in the central
nervous system. Preliminary studies show significantly
increased levels of neuroprostanes in brain regions in
Alzheimer's patients.'^
Gene expression
Regulation of gene expression of many different genes in
rat brain (for review see, Kitajka et al''') and other tissues
(for review, see Decklebaum et al'^). Rats fed throughout
life with either a vegetable oil (rich in ALA) or a fish oil-
rich diet (containing eicosapentaenoic acid (EPA) plus
DHA) showed highly significant alterations in the ex-
pression of more than 100 genes in the brain (approx
equal number over- and under-expressed). Of interest was
the fact that the ATP-generating machinery of the brain
responded to the dietary omega 3 PUFA most intensively.
The brain is known to exhibit a high metabolic rate and a
high proportion of this is used to maintain Na/K ATP-ase
activity, which regulates ion flow resulting from nerve
transmission. Genes involved in signal transduction were
also over-expressed, almost to same extent, by both the
ALA-rich and EPA plus DHA-rich diet. Also of interest
is that genes encoding for alpha- and gamma-synuclein
were over-expressed in young rats fed fish oil for one
month.'* Synucleins are associated with synaptosomes
and play a role in neural plasticity and learning. Alpha-
synuclein has also been implicated in the pathophysiol-
ogy of Parkinson's disease possibly via effects on
dopaminergic neurotransmission.''
Cellular events
[a] regulation of phosphatidyl serine levels which is in-
volved in the protection of neural cells from apoptotic
death, via effects on phosphatidylinositol 3-kinase/Akt
signaling,'^ [b] stimulation of neurite growth in hippo-
campal cells," [c] selective accumulation of DHA by
synaptic growth cones during neuronal development,^" [d]
regulation of neuron size,^' [e] regulation of nerve growth
factor,^ ^ and [f] stimulation of cell membrane expansion
by action on syntaxin 3 ." AA also demonstrated this ef-
fect. Taken together, these data provide strong support for
the role of DHA in the growth of neuronal cells and the
protection of cells from apoptosis.
What is the role of omega 3 fatty acids in neuropsy-
chiatric disorders?
Manic-depressive illness (bipolar disorder), depression
and schizophrenia are common neuropsychiatric disorders.
The incidence of depression has increased markedly in
the past decades in western countries.^" Epidemiological
evidence suggests that the condition has both genetic and
environmental components. In 1995, it was hypothesized
that a low omega 3 PUFA status could predispose sub-
jects to an increased risk of suicide and depression.^'
Shortly after this, several studies reported that low omega
3 PUFA levels in serum phospholipids, cholesteryl esters
and erythrocyte membranes were positively associated
with depression. '^'^ ^
The exact mechanisms involved in the pathogenesis of
depression are not knovra, however there are many effec-
tive treatments such as various antidepressant medica-
tions or electroconvulsive treatment.^ * The main drugs of
choice were discovered by chance in the middle of last
century and are known as tricyclic agents or monoamine
oxidase inhibitors. These inhibit re-uptake transporters of
serotonin and norepinephrine or inhibit the oxidation of
monoamine neurotransmitters (stopping the catabolism).
The treatments are not effective in all cases, with esti-
mates that only about half of all patients demonstrate a
complete remission although about 80% show some bene-
fit.^«
There are a number of parallels between the neural
systems affected in depression and those affected in die-
tary deficiency of omega 3 PUFA (Table 1). This paper
discusses these and the results of research trials of omega
3 PUFA in treating depression.
[1] Altered neurotransmission in major depression In
omega 3 PUFA deficient rats, the expression of the do-
pamine receptor (D2R) is decreased in the frontal cortex
and increased in the nucleus accumbens.^' In these studies,
the release of dopamine was significantly reduced how-
ever the picture is complex revealing a more active
mesolimbic dopamine pathway compared with a less ac-
tive mesocortical pathway in the omega 3 PUFA deficient
rats. In contrast to this, supplementing the diet of rats
with omega 3 PUFA (EPA and DHA) led to a 40% in-
crease in dopamine levels in the frontal cortex as well as
an increase in the binding to the dopamine D2 receptor.^"
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Tabie 1. Comparison of effects of depression and omega 3 PUFA on various neural parameters
Item Depression Deficiency of omega 3PUFA Addition of omega 3 PUFA
Neurotransmission
Glucose metabolism in brain
Neuronal atrophy
BDNF levels in brain
Treatment maintains levels of Decreased levels of
AA metabolism in brain
Pro-inflammatory cytokine levels Increased
neurotransmitters
Reduced metabolism.








Increased levels of dopamine
and increased binding to D2
receptordopamine and D2 receptor
Reduced uptake of glucose
via glucose transporter
Increases AA turnover &
metabolism
Reduced
DHA promotes neural cell
growth and reduces apoptosis
Decreased by deficiency. Increased by omega 3 PUFA,
diets high in saturated fat & exercise, vitamin E, and
sucrose and COX inhibitor prostaglandins
[2] In major depression there are reports of decreased
cerebral blood flow'' and reduced glucose metabolism."
As noted above, omega 3 PUFA deficiency decreases
glucose uptake of brain cells and cytochrome oxidase
activity by at least 30%; both are measures of functional
neuronal activity.'"*
[3] Depression is associated with excessive production of
pro-inflammatory cytokines, including interleukin (IL)-
lbeta, IL-12, IL-6, interferon-gamma and tumour necrosis
factor-alpha."'^'' Some anti-depressant medications can
inhibit the release of these cytokines.^'
Omega 3 PUFA are well known to inhibit the produc-
tion of pro-inflammatory cytokines, via effects in reduc-
ing the production of pro-inflammatory prostaglandins
(PGEj) and leukotrienes (LTB4)."
[4] Major depression is associated with neuronal atrophy
(decrease in density and size of neurones) in the hippo-
campus & prefrontal cortex."'^*
As noted above, the literature provides strong support
for the role of DHA in the growth of neuronal cells and
the protection of cells from apoptosis.'*
[5] There is evidence of a link between brain-derived neu-
rotrophic factor (BDNF) and depression. BDNF is a
widely distributed trophic factor in the brain, and it is
involved in neuronal growth, maintenance and neural
plasticity.'' Chronic administration of antidepressants is
associated with an increased (normalized) serum level of
BDNF."" BDNF expression can be altered by both exer-
cise and components of the diet. Its expression is inhib-
ited by a diet high in saturated fat and sucrose,"' however
high levels of vitamin E or exercise can restore the level
of BDNF."*^ '"' It has been shown recently that omega 3
PUFA can normalize BDNF levels and counteract the
learning disability after traumatic brain injury in rats.""
Rao et al''" have reported that omega 3 PUFA deficiency
in rats leads to a reduced expression of BDNF in the fron-
tal cortex, and that addition of DHA to cultured rat corti-
cal astrocytes induced BDNF protein expression. Another
report in murine astrocyte cultures showed that pros-
taglandins D2 and E2, derived from membrane AA, are
powerful inducers of nerve growth factors and BDNF."'
Consistent with this, Shaw et al"* reported that the broad
spectrum cyclooxygenase inhibitor, ibuprofen, reduced
exercise-induced increases in BDNF and PGE2 levels,
and blocked long-term potentiation and spatial learning in
rats.
Trials of omega 3 PUFA in mood disorders
The observations linking the omega 3 PUFA to neural
fiinction and perhaps depression have led to a number of
intervention studies in patients with depression. Results
from case-control studies, clinical trials and case studies
have shown that oils rich in omega 3 PUFA play a bene-
ficial role in these conditions. Readers might also wish to
consult a recent review of the evidence and method cri-
tique on omega 3 PUFA and depression."' Various omega
3 fatty acids have been considered in relation to mood
disorders, including the ethyl ester of EPA (ethyl-EPA),
DHA or mixtures of EPA and DHA as found in fish oil.
One ofthe first intervention studies was a 4-month dou-
ble-blind, placebo-controlled trial in 30 patients on stan-
dard medication, aged 18 to 65 years, with bipolar disor-
der."* This study showed that episodes of severe mania
and depression were significantly reduced in the omega 3
PUFA (EPA plus DHA) supplementation group (n=14)
(9.6g/day) compared with the placebo group (n=16). Peet
and Horrobin"' studied 70 patients with persistent depres-
sion, despite treatment with standard anti-depressants.
The patients were randomized to receive 1, 2 or 4 g of
pure ethyl-EPA per day or placebo for 12 weeks in addi-
tion to their usual medication. Interestingly, only those
patients treated with 1 g/day (n=17) showed a significant
improvement (reduction in the depression rating); in this
group, 69% of patients showed a reduction of at least
50% of the symptoms rated on a standard depression rat-
ing scale compared with 25% of patients so improving in
the placebo group. Another study in 20 patients with re-
current unipolar depression on their standard antidepres-
sant medication, showed that there were highly signifi-
cant benefits from ethyl-EPA (2 g/day), compared with
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placebo after 3 weeks of treatment.'" In a double-blind
study, subjects with major depressive disorder were ran-
domized to receive either 3.3 g/day of EPA plus DHA
(from fish oil) or placebo for 8 weeks in addition to usual
treatment." Patients in the omega 3 PUFA treated group
had a significantly decreased score on the Hamilton Rat-
ing Score for depression compared with the placebo
group (P<0.001). However, a double-blind study in 36
depressed patients who received 2 g/day of DHA for 6
weeks as monotherapy showed no significant effect com-
pared with the placebo treatment.'^
An open-label study in 12 bipolar patients treated with
1.5 to 2.0 g of EPA/day for up to 6 months showed bene-
ficial effects in 8 out 10 patients who completed 1 month
of the treatment." In contrast. Silvers et aF" reported that
8 g of fish oil per day for 12 weeks in addition to usual
medication in a randomized double-blind study showed
no significant improvement in mood, over the placebo of
olive oil, in 77 participants being treated for depression.
Frangou et al" conducted a 12-week double blind study
in 75 individuals with bipolar depression with 1 g/day or
2 g/day of ethyl-EPA as adjunctive therapy. There was a
significant improvement with the ethyl-EPA (no dose
response effect) based on the Hamilton rating scale and
the clinical global impression scale. However, Keck et
al'* reported no significant effect of ethyl-EPA in indi-
viduals with bipolar depression and rapid cycling bipolar
disorder. The study was conducted using 6 g/day of
ethyl-EPA as adjunctive therapy for 4 months in a ran-
domized, placebo-controlled study.
A single case report has found that ethyl-EPA given to
a treatment-resistant, severely depressed and suicidal
male patient, resulted in dramatic and sustained clinical
improvement in all symptoms of depression within one
month." The EPA treatment was accompanied by a re-
duction in the lateral ventricular volume in the brain.
Noaghuil and Hibbeln'* investigated cross-national
prevalence rates of bipolar disorders and showed that
there was a very strong relationship between greater sea-
food consumption and lower prevalence rates. Regular
consumption of fish bas also been associated with re-
duced suicidal ideation" and better self-reported mental
health status.*"
In a cross-national study of prevalence rates of post-
partum depression and breast milk EPA, DHA and AA
levels and seafood consumption, Hibbeln*' found that
higher concentrations of DHA in milk and greater sea-
food consumption both predicted lower prevalence rates
of past-partum depression. However, two studies in post-
partum depression have failed to demonstrate an effect of
omega 3 PUFA. A small pilot open-label study in seven
pregnant females with a past history of post-partum de-
pression, who were provided 2.96 g of EPA plus DHA
(provided as fish oil) for 2 weeks prior to birth, failed to
show promising results.*^ Llorente et al*' reported that 2
g/day of DHA provided to breast-feeding mothers in the
first four months after birth led to no changes in self-
rating or diagnostic measures of depression compared
with the placebo group.
In summary, seven of the ten studies in adults with
depression or bipolar disorder (excluding post-partum
depression) have reported positive effects of either fish
oil containing EPA and DHA (3.3 and 9.6 g/day) or ethyl-
EPA (1-2 g/day). The three negative studies were with
DHA alone (2g/day), fish oil (8g/day) and ethyl-EPA at
4-6 g/day. This leaves some questions for which we do
not have adequate answers at this stage.
Question 1: which omega 3 PUFA is best to treat mood
disorders (EPA or a mixture of EPA plus DHA)?
Question 2: what is the most effective dose?
Question 3: what is the most effective length of treatment?
Question 4: does the use of omega 3 PUFA give the most
benefit in patients on usual medication?
Question 5: what is the mechanism of action of EPA? It
should be noted that there is a lack of studies in animals
that have examined the role of EPA in neural fiinction
and also that brain grey matter contains negligible levels
of EPA.*"
It is of considerable interest that there is a relationship
between depression and heart disease. For example, pa-
tients with an episode of major depression have a 3-fold
risk of cardiac mortality later in life.*' It is possible that
the link between these conditions is that both have been
associated with low intakes of omega 3 PUFA.
Mechanisms
Biophysical properties of synaptic membranes directly
affect neurotransmitter biosynthesis, signal transduction,
uptake of serotonin, binding of a-adrenergic and seroton-
ergic receptors, and monoamine oxidase activity. The
proposed mechanisms of action of the omega 3 PUFA in
mood disorders include effects on neurotransmitter recep-
tors and G-proteins via effects on biophysical properties
ofthe membrane, effects on secondary messengers and on
protein kinases, and effects on the inflammatory response
of eicosanoids derived from AA.
Recent data in rats reveal that the drugs commonly
used to treat bipolar disorder, lithium, carbamazapine and
valproic acid, significantly decrease the turnover of AA
and metabolism to eicosanoids in the brain (see below).
This new information reveals the possibility of a link be-
tween omega 3 PUFA and mood disorders, given that
deficiency of omega 3 PUFA leads to an increased me-
tabolism of AA to eicosanoids, via specific phospholipase
A2 and cyclooxygenase enzymes (COX-2) in rat frontal
cortex.'"
Rats treated with lithium and carbamazapine demon-
strated a reduced turnover of AA, but not DHA, in brain
phospholipids and decreased mRNA, protein levels and
enzyme activity of a cytosolic phospholipase A2, which is
AA-specific.**'*' This treatment also reduced the brain
concentration of prostaglandin E2, a product of the COX
pathway, presumably due to reduced release of AA from
the phospholipids. It is possible that EPA is effective in
depression through its ability to inhibit COX activity,
although the levels of EPA in the brain phospholipids are
very low.
The same group showed that another drug used in treat-
ing bipolar disorder, valproic acid, also reduced AA turn-
over in the brain but by a different mechanism, namely
the inhibition of the formation of arachidonoyl CoA.** It
is of interest that two further papers from this group dem-
onstrate effects of chronic lithium on the elevation of
brain glucose metabolism*' and on dopamine D2
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receptor-initiated signalling, via effects on AA tumover
in the brain.'"
Conclusions
DHA plays an important role in the structure and function
of brain cellular membranes. There is biologically plau-
sible evidence to suggest that omega 3 PUFA might play
a role as adjunctive therapy for adult depression, though
much research is required to determine the most effective
omega 3 PUFA (EPA, DHA or a mixture of both) and the
most effective dose.
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